Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Rating of “Moderate Buy” from Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.64.

Several brokerages have recently issued reports on GOSS. Sumitomo Mitsui Financial Group cut Gossamer Bio from an “outperform” rating to a “neutral” rating and set a $3.00 price objective for the company. in a report on Wednesday, December 7th. Raymond James dropped their price objective on Gossamer Bio from $18.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, November 17th. Barclays cut shares of Gossamer Bio from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $18.00 to $2.00 in a research note on Wednesday, December 7th. JPMorgan Chase & Co. cut shares of Gossamer Bio from a “neutral” rating to an “underweight” rating in a research note on Wednesday, December 7th. Finally, HC Wainwright decreased their target price on shares of Gossamer Bio from $25.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, December 8th.

Insider Buying and Selling

In other news, insider Laura Carter sold 4,876 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $12.07, for a total value of $58,853.32. Following the completion of the sale, the insider now directly owns 82,292 shares in the company, valued at $993,264.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Caryn Peterson sold 4,757 shares of the business’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $12.07, for a total value of $57,416.99. Following the completion of the sale, the executive vice president now owns 61,415 shares of the company’s stock, valued at approximately $741,279.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Laura Carter sold 4,876 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $12.07, for a total transaction of $58,853.32. Following the completion of the sale, the insider now directly owns 82,292 shares of the company’s stock, valued at $993,264.44. The disclosure for this sale can be found here. 8.30% of the stock is owned by company insiders.

Institutional Trading of Gossamer Bio

A number of hedge funds have recently bought and sold shares of GOSS. Point72 Hong Kong Ltd bought a new position in Gossamer Bio during the 1st quarter worth approximately $33,000. Great West Life Assurance Co. Can bought a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $57,000. Amalgamated Bank bought a new position in Gossamer Bio during the 1st quarter valued at $65,000. Denali Advisors LLC purchased a new stake in Gossamer Bio in the 2nd quarter worth about $75,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in Gossamer Bio in the 3rd quarter worth approximately $121,000. 90.18% of the stock is owned by institutional investors.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $2.34 on Tuesday. Gossamer Bio has a 1-year low of $1.57 and a 1-year high of $15.19. The stock’s 50-day moving average is $5.01 and its 200-day moving average is $9.66. The company has a current ratio of 5.93, a quick ratio of 5.93 and a debt-to-equity ratio of 3.73. The stock has a market cap of $221.08 million, a P/E ratio of -0.81 and a beta of 1.12.

Gossamer Bio (NASDAQ:GOSS – Get Rating) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.01. Equities research analysts anticipate that Gossamer Bio will post -2.75 earnings per share for the current year.

About Gossamer Bio

(Get Rating)

Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.